Skip to main content

Rezwanul Wahid, MBBS, PhD

Academic Title:

Associate Professor

Primary Appointment:



HSF II, 330

Phone (Primary):




Education and Training

Dhaka Medical College, Bangladesh, Bachelor of Medicine and Surgery (MBBS), 1987

Kagoshima University School of Medicine, Japan, Ph.D., 1996

Clinical Fellow, Dhaka Children’s Hospital, Dhaka Bangladesh, Pediatrics, 1987-1988

Postdoctoral Research Fellow, Kagoshima University, Japan, Pediatrics, 1999-2001

Postdoctoral Research Fellow, University of Maryland Center for Vaccine Development, 2001-2007


Dr. Wahid specializes in vaccine immunology and evaluates immunogenicity of various vaccines to identify their efficacy and correlate of protection.  He studies the role of antigen-specific multi-functional memory T and B cells as well as functional antibodies in protection against human diseases.

Research/Clinical Keywords

Vaccine, immunology, infectious disease, T and B cell immunity, translational research.

Highlighted Publications

A complete list of published work is available in MyBibliography.

Wahid R, Fresnay S, Levine MM, Sztein MB. Cross-reactive multifunctional CD4+ T cell responses against Salmonella enterica serovars Typhi Paratyphi A and Paratyphi B in humans following immunization with live oral typhoid vaccine Ty21a. Clin Immunol. 2016 Sep 12.

Wahid R, Fresnay S, Levine MM and Sztein MB. Immunization with Ty21a live oral typhoid vaccine elicits cross-reactive multifunctional CD8+ T cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A and S. Paratyphi B in humans. Mucosal Immunol. 2015 Nov;8(6):1349–1359.

Wahid R, Zafar SJ, McArthur MA, Pasetti MF, Levine MM, Sztein MB. Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B. Clin Vaccine Immunol. 2014 Mar;21(3):427-34.

Wahid R*, Simon JK*, Picking WL, Kotloff KL, Levine MM, Sztein MB (*equal contributing first author). Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. Clin Immunol. 2013;148:35-43.

Davis CL, Wahid R, Toapanta FR, Jakub K. Simon JK, Sztein MB and Levy D. Applying mathematical tools to accelerate vaccine development: Modeling Shigella immune dynamics. PloS One. 2013;8(4):e59465.

Additional Publication Citations

Ramirez K*, Wahid R*, Richardson C, Bargatze RF, El-Kamary SS , Sztein MB and Pasetti MF (*equal contributing first author). Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. Clin Immunol. 2012;144(2):98.

Wahid R, Simon R, Zafar SJ, Levine MM, Sztein MB. Live oral typhoid vaccine Ty21a induces cross reactive humoral immune responses against S. Paratyphi A and S. Paratyphi B in humans. Clin Vaccine Immunol. 2012;19(6):825.

Ruiz-Perez F, Wahid R, Faherty CS, Kolappaswamy K, Rodriguez L, Santiago A, Murphy E, Cross A, Sztein MB and Nataro JP. Serine protease autotransporters from Shigella flexneri and pathogenic Escherichia coli target a broad range of leukocyte glycoproteins. PNAS. 2011;108(31):12881-6.

Simon JK, Maciel M Jr, Weld ED, Wahid R, Pasetti MF, Picking WL, Kotloff KL, Levine MM, Sztein MB. Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidate. Clin Immunol. 2011;139(2):185-92.

Wahid R, Pasetti MF, Maciel M Jr., Simon JK, Tacket CO, Levine MM, Sztein MB. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+ IgD- S. Typhi specific IgA and IgG B memory cells in humans. Clin Immunol. 2011;138(2):187-200.

Research Interests

Dr. Wahid has been working in the field of translational research for more than 18 years focusing on the human host- immune responses elicited by natural infection or immunization with various vaccines. The ultimate goal of his research is to enhance the development of novel vaccines against various diseases, by understanding various vaccine elicited immune mechanism that can be correlated with protection.  He utilizes state of the art technologies such as multi-color flow cytometry, cytokine assays, ELISA, B and T cell ELISPOT assays among others, to measure and quantify the induction of critical antigen-specific functional antibodies, as well as, multifunctional memory/effector T and B cells in volunteers following immunization with vaccines (against Salmonella, Shigella, Norovirus, Ebola etc). He is collaborating with other researchers to understand the mechanism of parasites or bacterial infections (i,e., enteropathogenic E. Coli) in evasion and modulation of host-immune responses.

Grants and Contracts

Marcelo B Sztein, M.D. (PI)
Role: Co-Investigator
R01 AI36525
National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)
Immune mechanisms of protection in S. Typhi vaccines

  • The purpose of this grant is to identify at the local and systemic levels T cell-mediated immune responses induced by oral immunization with new generation attenuated S. Typhi strains and identify the cellular and molecular mechanisms that best correlate with protection.

Myron M. Levine, M.D., D.T.P.H. (PI)
Role: Co-Investigator
U19 AI109776
Immunoprophylactic Strategies to Control Emerging Enteric Infections, Enteric Center for Excellence in Translation Research (Enteric CETR) Network

  • The goal of this project is to develop products to prevent enteric disease caused by several important bacterial and protozoal pathogens.

Marcela F. Pasetti, Ph.D. (PI)
Role: Co-Investigator
PATH- Enteric Vaccine Initiative (EVI) DMID protocol 12-0023
Immunological evaluation of ETEC vaccine candidate dmLT

  • This project involves performing immunological studies for a NIAID-supported clinical study to test the E. coli heat labile toxin double mutant dmLT as an enteric adjuvant.            

Myron M. Levine, M.D., D.T.P.H. (PI)     
Role: Co-Investigator    
GSK consortium 2015
Safety and immunogenicity study of GSK Biologicals’ investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (GSK3390107A) in children in Africa

Wilbur Chen, M.D., M.S. (RTOP PI); Karen Kotloff, M.D. (Vaccine and Treatment Evaluation Units (VTEU) PI)
Role: Lab Co-Investigator
DMID Protocol 14-0031
Phase I Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and lmmunogenicity of Double Mutant Heat-Labile Toxin L TR 192G/L211 A (dmL T) from Enterotoxigenic Escherichia coli (ETEC by oral, sublingual, and intradermal vaccination in adults residing in an endemic area)

Marcelo Sztein, M.D. (RTOP PI); Karen Kotloff, M.D. (VETU PI)
Role: Co-Investigator   
DMID Protocol: 14-0033
VTEU Consultation and Testing of Cytokine Levels and Cell Activation in Clinical Samples